Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Cancer Discovery|April 5, 2019
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in HematopoiesisJong Jin Jeong, Xiaorong Gu, Ji Nie, et al.
Blood Advances|November 19, 2019
Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysisKathy L McGraw, Chia-Ho Cheng, Y Ann Chen, et al.
Blood|June 17, 2022
A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventionsTae-Hoon Shin, Yifan Zhou, Shirley Chen, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
Pageof 20